CUE (Cue Biopharma, Inc.) Stock Analysis - Analyst Ratings

Cue Biopharma, Inc. (CUE) is a publicly traded Healthcare sector company. As of May 21, 2026, CUE trades at $20.03 with a market cap of $86.50M and a P/E ratio of -16.45. CUE moved -1.53% today. Year to date, CUE is +77.99%; over the trailing twelve months it is +1.70%. Its 52-week range spans $4.97 to $59.67. Rallies surfaces CUE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate CUE?

The average price target is $0.00.

CUE Key Metrics

Key financial metrics for CUE
MetricValue
Price$20.03
Market Cap$86.50M
P/E Ratio-16.45
EPS$-1.21
Dividend Yield0.00%
52-Week High$59.67
52-Week Low$4.97
Volume119.22K
Avg Volume0
Revenue (TTM)$32.73M
Net Income$-19.52M
Gross Margin0.00%

CUE Analyst Consensus

CUE analyst coverage data. Average price target: $0.00.

Latest CUE News

Recent CUE Insider Trades

  • Sarraf Pasha bought 4.23K (~$1.31K) on Dec 30, 2025.
  • Sarraf Pasha bought 77.15K (~$23.17K) on Dec 30, 2025.
  • Sarraf Pasha bought 86.95K (~$27.60K) on Dec 30, 2025.

Common questions about CUE

What do analysts rate CUE?
The average price target is $0.00.
Does Rallies show CUE price targets?
Yes. Rallies tracks CUE analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is CUE research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CUE. It does not provide personalized investment advice.
CUE

CUE